ArticleFrontiers in nutrition2026
Insulin resistance evaluated by estimated glucose disposal rate and its association with cardiometabolic risk factors among adolescents in Northeast China.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Insulin resistance (IR) is a key factor in cardiometabolic diseases, but there are few practical ways to measure it in adolescents. The insulin sensitivity's surrogate measure, the eGDR, has not been well validated in young populations. Methods: eGDR was determined by the use of waist circumference (WC), HbA1c levels, and hypertension status in this cross-sectional study of Chinese adolescents. Restricted cubic spline models and multivariate logistic regression were utilized to estimate associations between eGDR and cardiometabolic risk factors (CMRFs), such as dyslipidemia, hyperuricemia, and high fasting plasma glucose (FPG). The eGDR's discriminative performance was compared with traditional IR indices, such as HOMA-IR, TyG, AIP, TyG-BMI, and QUIKI. Results: After confounders' adjustment, each SD raise in eGDR was linked with reduced odds of dyslipidemia (OR = 0.781, 95% CI: 0.703-0.866, Conclusion: eGDR is a strong, non-invasive cardiometabolic risk indicator in adolescents, especially dyslipidemia and hyperuricemia. It can offer a feasible instrument of early risk stratification in this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.